Molecular docking of SP40 peptide towards cellular






Molecules 2021, 26, 6576. https://doi.org/10.3390/molecules26216576 www.mdpi.com/journal/molecules 
Article 
Molecular Docking of SP40 Peptide towards Cellular  
Receptors for Enterovirus 71 (EV-A71) 
Malihe Masomian *, Salima Lalani and Chit Laa Poh * 
Centre of Virus and Vaccine Research, School of Medical and Life Science, Sunway University, Bandar Sun-
way, Selangor 47500, Malaysia; salima.l@imail.sunway.edu.my 
* Correspondence: malihem@sunway.edu.my (M.M.); pohcl@sunway.edu.my (C.L.P.); Tel.: +603-74918622 
(Ext 7603) (M.M.); +603-74918622(Ext 7338) (C.L.P.) 
Abstract: Enterovirus 71 (EV-A71) is one of the predominant etiological agents of hand, foot and 
mouth disease (HMFD), which can cause severe central nervous system infections in young chil-
dren. There is no clinically approved vaccine or antiviral agent against HFMD. The SP40 peptide, 
derived from the VP1 capsid of EV-A71, was reported to be a promising antiviral peptide that tar-
geted the host receptor(s) involved in viral attachment or entry. So far, the mechanism of action of 
SP40 peptide is unknown. In this study, interactions between ten reported cell receptors of EV-A71 
and the antiviral SP40 peptide were evaluated through molecular docking simulations, followed by 
in vitro receptor blocking with specific antibodies. The preferable binding region of each receptor 
to SP40 was predicted by global docking using HPEPDOCK and the cell receptor-SP40 peptide com-
plexes were refined using FlexPepDock. Local molecular docking using GOLD (Genetic Optimiza-
tion for Ligand Docking) showed that the SP40 peptide had the highest binding score to nucleolin 
followed by annexin A2, SCARB2 and human tryptophanyl-tRNA synthetase. The average Gold-
Score for 5 top-scoring models of human cyclophilin, fibronectin, human galectin, DC-SIGN and 
vimentin were almost similar. Analysis of the nucleolin-SP40 peptide complex showed that SP40 
peptide binds to the RNA binding domains (RBDs) of nucleolin. Furthermore, receptor blocking by 
specific monoclonal antibody was performed for seven cell receptors of EV-A71 and the results 
showed that the blocking of nucleolin by anti-nucleolin alone conferred a 93% reduction in viral 
infectivity. Maximum viral inhibition (99.5%) occurred when SCARB2 was concurrently blocked 
with anti-SCARB2 and the SP40 peptide. This is the first report to reveal the mechanism of action of 
SP40 peptide in silico through molecular docking analysis. This study provides information on the 
possible binding site of SP40 peptide to EV-A71 cellular receptors. Such information could be useful 
to further validate the interaction of the SP40 peptide with nucleolin by site-directed mutagenesis 
of the nucleolin binding site. 
Keywords: hand, foot and mouth disease; molecular docking; receptor blocking; nucleolin; 
SCARB2; annexin2; human tryptophanyl-tRNA synthetase 
 
1. Introduction 
Enterovirus 71 (EV-A71) belongs to the Enterovirus A species of the Picornaviridae 
family and is known to cause hand, foot and mouth disease (HMFD). It poses significant 
health risks to young children under 5 years of age and the infection has also been re-
ported in older children and adults [1]. HFMD has become a major public health problem 
as it was associated with several large-scale outbreaks in the Asia Pacific region [2]. There 
were significant morbidity and mortality in HFMD outbreaks from Taiwan and China [3–
5]. HFMD is generally a mild and self-limiting disease characterized by fever, rashes on 
the hands and feet, and mouth ulcers. Complications of HFMD infections include aseptic 
meningitis, brainstem encephalitis, acute flaccid paralysis and pulmonary edema which 
could lead to death [1,6,7]. In 2017, almost two million cases of HFMD, including 96 
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deaths, were recorded in China. Less than a year later, in July 2018, 1,381,685 cases of 
HFMD were reported, including 26 fatal cases [8]. The major pathogens involved in the 
majority of HFMD outbreaks were EV-A71 and CV-A16, but recent studies showed that, 
besides these two pathogens, other enteroviruses, such as CV-A6 and CV-A10, have 
emerged as significant pathogens from recent HFMD outbreaks [9–11].  
To date, three formalin-inactivated monovalent EV-A71 vaccines have been ap-
proved by the China Food and Drug Administration (CFDA) [12]. However, multiple 
boosters (every 6–12 months) are needed to elicit protective immunity against EV-A71 and 
there is no cross-protection against other enteroviruses [13]. Besides vaccines, an alterna-
tive approach is to develop antiviral agents for the treatment of HFMD by targeting the 
virus or the host cell. Since virus replication is dependent on the host cell, there is a need 
to select a target so that an effective and safe antiviral drug can be designed without harm-
ing the host. Most antiviral drugs are small-molecule inhibitors that target different stages 
of the viral life cycle by interacting with a virus or host proteins which are critical for 
attachment and virus replication [14]. However, continuous mutations could occur in the 
virus genome, frequently leading to resistance to small-molecule antiviral drugs [15]. De-
veloping peptides as antivirals, targeting either the virus or the host cell, could be effective 
strategies. The virus life cycle, comprising various stages, such as virus entry, virus repli-
cation and assembly, have been targeted for new antiviral discovery [16]. Since peptides 
can disrupt protein–protein interactions, they are effective as antivirals to inhibit receptor 
interaction with the virus.  
Enterovirus 71 is a single-stranded positive-sense RNA virus that relies on its VP1 
capsid protein to attach to target cells. To date, several receptors have been proposed to 
be involved in EV-A71 attachment and entry, such as human scavenger receptor class B 
member 2 (SCARB2) [17], P-selectin glycoprotein ligand-1 (PSGL-1) [18], heparan sulfate 
(HS) proteoglycan [19], annexin A2 [20], nucleolin [21], dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN) [22], fibronectin [23], human tryp-
tophanyl-tRNA synthetase (hWARS) [24], vimentin [25], human prohibitin (PHB) [26], 
human galectin-1 [27], human cyclophilin [28], and sialic acid [29]. SCARB2 is the only 
receptor that had been reported to be involved in the attachment and internalization of 
the virus following uncoating [30]. Besides, SCARB2, human cyclophilin was reported to 
be involved in entry and enhancing the uncoating of EV-A71virion [28]. For ease of read-
ing, we have collectively referred to them as receptors. 
A synthetic peptide, SP40 (15-mers, QMRRKVELFTYMRFD), derived from the VP1 
capsid of EV-A71 was shown to be a potential antiviral for inhibition of EV-A71 in human 
Rhabdomyosarcoma (RD) cells. SP40 could reduce cytopathic effects in RD cells caused 
by EV-A71 strains from genotypes A, B and C, with an IC50 ranging from 6–9.3 µM. The 
in vitro inhibitory study of SP40 showed that it significantly reduced the formation of 
infectious viral particles, total viral RNA and VP1 protein. Besides EV-A71, SP40 also ex-
hibited broad-spectrum antiviral activities against CV-A16 and poliovirus type 1 in RD 
cells [31]. Studies of the mechanism of action suggested that the SP40 peptide was not 
virucidal and it probably blocked viral attachment to the RD cells through direct interac-
tion with the cell receptor(s). SP40 might inhibit virus infection by attaching to one or 
more of the cell receptors. Interaction of the SP40 peptide with any of the attachment re-
ceptors could lead to inhibition of viral attachment and reduced EV-A71 infection [31]. So 
far, there is no available information on the attachment mechanism of the SP40 peptide to 
cell receptor(s). This study aims to determine the interaction site of the RD cells receptor(s) 
with SP40 peptide by in silico study through molecular docking analysis, followed by re-
ceptor blocking using specific antibodies for selected receptors.  
Due to a great deal of interest in therapeutic peptides, several protein-peptide dock-
ing techniques have been developed which lead the study and optimization for drug 
screening and design. The protein-peptide docking algorithms can be divided into two 
classes: 1) template-based docking, which uses structural data from the analogous pro-
tein-peptide complex, and 2) template-free docking that does not require any template 
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and is subdivided into global and local docking. A combination of global and local dock-
ing approaches could provide a different level of prediction accuracy and is determined 
by the amount of information supplied as an input for the interactions [32]. Global dock-
ing is performed via a coupled search for the peptide binding site and pose. In local dock-
ing, the search for peptide-bound conformation is limited to the vicinity of the expected 
binding site. There are several software packages developed for protein-peptide docking, 
such as GalaxyPepDock [33], MDockPeP [34], HPEPDOCK [35], CABS-dock [36], pepAT-
TRACT [37], DINC [38], AutoDock CrankPep (ADCP) [39], HADDOCK peptide docking 
[40] and GOLD (Genetic Optimization for Ligand Docking) [41]. The performances of 
these softwares have been evaluated using an extensive benchmark data set involving 185 
complexes with peptide length ranging from 5 to 20 residues by Weng et al. [42]. The 
study revealed that, in global docking, HPEPDOCK performed the best on the entire data 
set and in local docking, GOLD achieved the best performance based on the peptide 
length of 11–15 residues. 
HEPEDOCK is a webserver designed for blind protein-peptide docking through a 
hierarchical algorithm [35]. It considers the peptide flexibility through an ensemble of 
peptide conformations generated by the MODPEP program [43]. Global peptide docking 
is much more challenging due to the relatively larger search space compared to local pep-
tide docking. Blind peptide-docking algorithms, such as CABS-dock [36], pepATTRACT 
[37] and MDockPeP [34] required lengthy simulations in peptide binding refinement and 
mostly takes hours on a GPU or multi-core CPUs for docking a peptide. Among them, the 
pepATTRACT web server is fast, but peptide flexibility is not sufficiently considered be-
cause it only considers three idealized conformations for a peptide [44] while HPEPDOCK 
adequately considers peptide flexibility by generating a large number of peptide confor-
mations [35]. 
Unlike the good progress that can be made in docking small organic molecules to 
protein targets, the prediction of the complex structure between a peptide ligand and pro-
tein receptor is not easy because of the flexible nature of peptides. The Rosetta Flex-
PepDock web server provides an interface to high-resolution peptide docking (refine-
ment) protocol for the modeling of peptide–protein complexes implemented within the 
Rosetta framework [45]. Starting from a coarse model of interaction, FlexPepDock per-
forms a Monte Carlo Minimization-based approach to refine all degrees of freedom of 
peptides (rigid body orientation, backbone and side-chain flexibility) as well as protein 
receptor side chains conformations. 
GOLD is an automated ligand docking program for local docking that uses a genetic 
algorithm to explore the full range of ligand conformational flexibility with the partial 
flexibility of the protein in the vicinity of the protein active site [41]. “Goldscore-CS is the 
original scoring function that is made up of four components; protein-ligand hydrogen 
bond energy (external H-bond), protein-ligand van der Waals (vdW) energy (external 
vdW), ligand internal vdW energy (internal vdW), and ligand torsional strain energy (in-
ternal torsion).” In Goldscore, the higher fitness representing a higher affinity to the lig-
and. 
In this work, we present a screening strategy dedicated to the predictions for the cell 
receptor-SP40 peptide complexes using HPEPDOCK global docking tool [35] and high-
resolution FlexPepDock refinement and scoring [45] of the protein–peptide complex. Dur-
ing HPEPDOCK docking simulation, the search for the receptor–peptide interaction in-
terface covered the whole surface of the cell receptors. Subsequently, the top five refined 
receptors-SP40 peptide complexes were analyzed using GOLD software to search for the 
receptors with the highest binding score. In all steps, the 3D structure of cell receptors or 
the receptor-SP40 peptide complexes were energy minimized using the YASARA soft-
ware. Furthermore, validation, based on specific antibody inhibition, was performed to 
rationalize the analysis of molecular docking of SP40 peptide with EV-A71 receptors.  
2. Results and Discussion 
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2.1. Global Docking to Identify the Binding Site of Receptors to the SP40 Peptide 
The synthetic SP40 peptide comprising 15 amino acids, QMRRKVELFTYMRFD, was 
identified as an antiviral agent against EV-A71 infection through the screening of over-
lapping peptides covering VP1 [31]. The SP40 peptide has a molecular weight of 2.02 kDa 
with an isoelectric point of 9.98, an aliphatic index of 45.33 and grand average hydropathi-
city (GRAVY) of −0.833 (analyzed by ExPASy-ProtParam tool 
(https://web.expasy.org/protparam/) (accessed on 2 March 2021). The GRAVY value rep-
resents the hydrophobicity of a peptide and a positive GRAVY value indicates hydropho-
bicity, while the negative value indicates that the peptide is hydrophilic. The predicted 
three-dimensional structure of the SP40 peptide is a short α-helix. The hydrophobic sur-
face area of the SP40 peptide visualized by Discovery studio software is shown in Figure 
1A.  
The three-dimensional structure of the SP40 peptide has a molecular surface volume 
of 1909.25 Å3 and a molecular surface area of 1347.50 Å2 (analyzed by YASARA software). 
Analysis of the SP40 peptide by CELLPM (Figure 1B), a web-based tool aimed at validat-
ing the ability of peptides to passively penetrate across the lipid bilayer, showed that its 
log permeability coefficient is −30.17 [46]. Values of logPcalc > −5 indicate that the peptide 
might readily penetrate across the lipid bilayer. In wet-lab experimentation, the fluores-
cein-labeled SP40 peptide viewed with fluorescent microscopy showed that the SP40 pep-





Figure 1. Analysis of the predicted SP40 peptide. (A) Hydrophobic surface area. (B) Ability of SP40 peptide to passively 
penetrate across the lipid bilayer. 
In the first step, molecular docking of the SP40 peptide to target receptors of EV-A71 
was carried out using HPEPDOCK to identify the binding site of SP40 peptide in each 
reported cell receptor. The peptide flexibility was considered by generating an ensemble 
of 1000 peptide conformations. The sampled peptide conformations were globally docked 
against the whole protein using the MDock rigid docking protocol. The top 100 peptide 
binding models and the docking scores and rankings for the top 10 binding models were 
saved and presented (Supplementary Table S1). The docking scores provided by 
HPEPDOCK did not reflect the real binding affinities, but a relative ranking among dif-
ferent binding models.  
Based on the first round of global molecular docking, the overall binding sites of SP40 
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Figure 2. Generation of receptor SP40 peptide complex models resulting from global molecular docking via HEPEDOCK. 
The surface of the receptors and SP40 peptides are shown in wheat and blue colors, respectively. (A) Nucleolin, (B) Human 
cyclophilin, (C) Human galectin, (D) Fibronectin, (E) SCARB2, (F) DC-SIGN, (G) Annexin A2, (H) Human tryptophanyl-
tRNA synthetase l, (I) Vimentin and (J) Human prohibitin. 
Nucleolin is an abundant nucleolar phosphoprotein that can be found in organisms 
from yeasts to plants and mammals. Nucleolin is located mostly in dense fibrillar regions 
of the nucleolus and it is also expressed at the cell surface where it acts as a receptor for 
viruses, such as EV-A71 [21], poliovirus [47] and coxsackieviruses B serotypes 1 to 6 [48]. 
Nucleolin comprised three structural domains including an acidic N-terminal domain, 
two to four RNA binding domains (RBD), and a C-terminal RGG rich ‘‘tail’’ which are 
able to interact with different proteins. [49]. Su et al. [21] showed that nucleolin could bind 
to EV71-immunoprecipitated particles. The VP1 of EV-A71 was reported to interact di-
rectly with nucleolin and the binding of EV-A71 to RD cells could be inhibited by using 
an anti-nucleolin antibody. In addition, the knockdown of nucleolin expression in RD cells 
was shown to significantly reduce EV-A71 infection. On the other hand, the expression of 
human nucleolin in infected murine NH3T3 cells was able to increase the cytopathic ef-
fects caused by EV-A71 infection. Therefore, nucleolin was demonstrated to be an attach-
ment receptor responsible for EV-A71 entry [21]. The best available structure of nucleolin 
in the PDB database was the solution structure of the RBD1,2 domains from human nu-
cleolin (PDB ID 2KRR) that has two domains. The global docking showed that most of the 
SP40 peptide poses were bound to the region between RBD 1 and 2 domains as shown in 
Figure 2A and five of the top-scoring complexes were used for local docking.  
Cyclophilins are involved in several cellular processes, such as transcriptional regu-
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A is a highly abundant cytosolic protein that plays a significant role in the proliferation of 
several viruses [51]. Qing et al. [28] showed that cyclophilin A plays important role in EV-
A71 proliferation by using cyclophilin A inhibitors as a bioprobe. Cyclophilin A interacted 
with the VP1 of EV-A71, modified the conformation of the VP1 H-I loop and worked as 
an uncoating regulator in the EV-A71 entry step. The H-I loop is located in the VP1 of EV-
A71 amino acids 239-GSSKSKYPL-247. The uncoating regulatory ability of cyclophilin A 
has made it different from other attachment receptors reported previously. The cyclo-
philin A 3D structure comprises an eight-stranded antiparallel β-sheet barrel capped by 
α-helices [52]. The human cyclophilin A protein structure with PDB ID 5KUW contains 
165 amino acids. Global molecular docking showed that all of the SP40 peptide poses were 
located at the opposite side of the N- and C-terminal region, close to β-strand 3 (Figure 
2B). Therefore, the five top-scoring models generated by HPEPDOCK were used for the 
local docking study. Galectin-1 is a soluble beta-galactoside binding lectin that is ex-
pressed in mammalian tissues, such as the brain and lymphoid tissues [53]. It regulates 
neuron degeneration and immune responses and plays an important role in viral diseases 
[54,55]. Using confocal microscopy, Lee et al. [27] showed that galectin-1 could colocalize 
with EV-A71 in SK-N-SH or RD cells. The co-immunoprecipitation of galectin-1 and EV-
A71 from infected cells had shown that anti-galectin-1 antibody could precipitate the EV-
A71-galectin-1 complex, which was detected using immunoblotting with anti-EV-A71 an-
tibody and the anti-galectin-1 antibody. This indicated the interaction of galectin-1 with 
the EV-A71 during replication. EV-A71, which was propagated in SK-N-SH cells with ga-
lectin-1 gene knockdown, showed lower infectivity in the cell culture and less pathogenic-
ity in the mice compared to the virus that was propagated in the normal cell. Human 
galectin-1 could bind to the VP1 and VP3 of EV-A71 through carbohydrate residues and 
it could be released and interact with another cell surface along with the virus. [27]. The 
overall human galectin-1 3D structure comprises a two antiparallel β-sheet sandwich that 
adopts a closing hand shape. The backhand is formed by five strands (F1 to F5 which form 
the F-sheet), while the palm consists of six strands (S1 to S6 that form the S-sheet). The 
carbohydrate-binding site (CBS) is located in a groove in the S-sheet side of the sandwich, 
and the β-galactoside recognition core motif is mediated by sheets S4, S5, and S6. The β-
galactoside recognition core motif has been used for docking analysis for drug discovery 
[56]. In the global docking study, using HPEPDOCK, the majority of the poses were lo-
cated at the groove in the S-sheet side of the sandwich next to the carbohydrate-binding 
site, but few were bound to the surface of the F-Sheet side of the antiparallel β-sheets. 
(Figure 2C). However, the top five poses of SP40 peptide were placed at the carbohydrate-
binding site which was used for local docking (Supplementary Figure S1).  
Fibronectin is a high-molecular-weight extracellular matrix glycoprotein with a mul-
tidomain structure. The arginine-glycine-aspartic acid (RGD) binding site of fibronectin 
was shown to bind to integrin α5β1, which is a specific receptor for fibronectin. Cells me-
diate the fibronectin matrix assembly through integrin binding to the RGD (Arg-Gly-Asp) 
cell-binding domain. [57]. He et al. [23] indicated that the overexpression of fibronectin 
enhanced EV71 infection, while the knockdown of the fibronectin could greatly reduce 
viral yield and diminished viral binding to host cells. A synthetic, Arg-Gly-Asp-Ser 
(RGDS) peptide with the sequence known as the fibronectin motif could significantly in-
hibit the replication of EV-A71 in cell cultures and neonatal mice. It was shown that the 
N-terminal fragment of VP1 of EV-A71 interacted with the D2 domain of fibronectin. The 
finding demonstrated that EV-A71 particles bound to the fibronectin and facilitated virus 
entry [23]. The only protein structure of the cell-binding domain comprising amino acids 
1358–1631 in the protein database which corresponded with the human fibronectin en-
compassing the RGD loop and synergy region with PDB ID 1FNF. The structure of the 
fibronectin cell-binding domain contained four contiguous fibronectin-III modules in an 
extended rod-like molecule with a long axis of around 140 Å. The global molecular dock-
ing study showed that most SP40 poses were at the first and third contiguous regions, 
which also bound to the C-terminal of the protein and close to the RGD loop (Figure 2D). 
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The top 5 scored poses of SP40 peptide were placed at the third contiguous region and C-
terminal close to the RGD loop. This region was used for the local docking. 
Scavenger receptor class B, member 2 (SCARB2) is a type III transmembrane protein 
which is known as lysosomal integral membrane protein II and is a major receptor in-
volved in EV-A71 infection. SCARB2 supports the attachment and internalization of EV-
A71 and was shown to initiate conformational changes that steer the uncoating of viral 
RNA in the cytoplasm in RD and Vero cells [58]. The three-dimensional structure of the 
EV-A71-SCARB2 receptor complex was determined by cryo-electron microscopy [59]. The 
SCARB2 structure contains a large anti-parallel β-barrel with many short α-helical seg-
ments. At the top of the anti-parallel β-barrel, three α-helices, α-4, α-5 and α-7 with an-
other 2 short helices and the β7 strand constitute the head region of the SCARB2 that is 
considered as the extracellular domain and it is exposed at the cell surface. SCARB2 also 
has a short cytoplasmic domain at the amino- and carboxy-termini. The structural confor-
mation of SCARB2 is pH-dependent and His-150 plays an important role in switching the 
neural form that binds to the β-glucocerebrosidase (β-GC) to the acidic form that does not 
bind. Two α-helices in the head region [α-5 (amino acid no. 153–163) and α-7 (amino acid 
no. 183–193)] of SCARB2 bind to the GH loop of VP1 and the EF loop of VP2 capsid pro-
teins of EV-A71. SCARB2 has been shown to uncoat the EV-A71 RNA in a low pH-de-
pendent manner [60]. Besides SCARB2, other cell receptors were reported to support the 
surface binding of EV-A71[30]. Global docking showed that the majority of the SP40 pep-
tide poses were placed close to the cavity in the large anti-parallel β-barrel and also in the 
concavity under the head domain of SCARB2 (Figure 2E). The top five scoring poses were 
placed in the cavity under the head domain, which was used for local docking.  
Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN) is a calcium-dependent C-type lectin receptor [61-62] that is expressed in dendritic 
cells (DCs), macrophages, activated B cells, skin dermis, placenta, intestinal and genital 
mucosa, and lymphoid tissues [61,63-66]. It binds to oligosaccharide ligands found on hu-
man tissues as well as to pathogens including viruses, bacteria, and parasites. The extra-
cellular portion of this receptor contains a membrane-distal carbohydrate-recognition do-
main (CRD) and forms tetramers stabilized by an extended neck region consisting of 23 
amino acid repeats. The intact receptor has a tetrameric state. Hydrodynamic studies on 
truncated receptors demonstrate that the portion of the neck of the protein adjacent to the 
CRD is sufficient to mediate the formation of dimers, whereas regions near the N-termi-
nus are needed to stabilize the tetramers. Crystallization study of truncated receptors 
showed that CRDs are flexibly linked to the neck, which contains α-helical segments in-
terspersed with non-helical regions. The flexibility of the CRDs in the tetramer along with 
data on the specificity of these receptors showed a significant role for oligomerization in 
the recognition of endogenous glycans, in particular those present on the surfaces of en-
veloped viruses recognized by these proteins [67]. There are a few viruses that can abduct 
DC-SIGN receptor to spread such as the measles virus, hepatitis C virus and HIV [68-70]. 
Ren et al. [22] reported that monocyte-derived dendritic cells (MDDCs) could capture EV-
A71 through viral binding to DC-SIGN, and these surface-bound viral particles could be 
transferred to susceptible cells for robust infection. The full-length DC-SIGN consists of 
268 amino acids encoded by the gene CD209. The 3D structures of DC-SIGN available in 
the protein database contain 139 to 170 amino acids and the neck region of the structure 
did not appear in those crystal structures. Therefore, by using five templates of the DC-
SIGN retrieved from PDB, a new structure was predicted which contained amino acids 38 
to 260. The templates were crystal structures of DC-SIGN_CRD with PDB ID 1SL4 which 
consists of 155 amino acids, PDB ID 1SL5 which consists of 139 amino acids, PDB ID 2IT5, 
which consists of 139 amino acids, PDB ID 2IT6 which consists of 155 amino acids and 
PDB ID 2XR6 which consists of 170 amino acids. The predicted structure of DC-SIGN was 
used for the docking study. The global docking investigation showed that most of the 
SP40 peptide poses were bound to the CRD and neck domains on both sides of the protein 
(Figure 2F). For local docking, the five top-scoring SP40 peptide poses were used.  
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Annexin A2 is a calcium- and phospholipid-binding protein that acts as a profibrino-
lytic co-receptor in tissue plasminogen activator and plasminogen on endothelial cells 
[71]. Besides that, it is involved in endocytosis, exocytosis, membrane domain organiza-
tion, actin remodeling, signal transduction, protein assembly, transcription and mRNA 
transport, and DNA replication and repair [72]. Yang et al. [20] showed that EV-A71 could 
bind to annexin A2 through VP1 in RD cells. Both pretreatments of EV-A71 with soluble 
recombinant annexin A2 or pretreatment of host cells with an anti-annexin A2 antibody 
reduced viral attachment to the cell surface and subsequently reduced the virus yield in 
vitro. The VP1 amino acids 40 to 100 are the annexin A2-interacting domain that had been 
mapped by yeast two-hybrid analysis. Annexin A2 was shown in pull-down assay that it 
could directly bind to five strains of enterovirus 71 belonging to different sub-genotypes 
C2, C5, and B5 whereas CV-A16 did not bind to annexin A2. Annexin A2 in human cells 
is encoded by the ANXA2 gene and it is translated to 338 amino acids. The 3D structure 
of annexin A2 is divided into four homologous repeats (I–IV) and each comprises a struc-
turally similar domain containing five α-helices. The entire molecular structure looks like 
a curved disk with the four subdomains arranged in a near-parallel pattern. In this study, 
the crystal structure of a non-mutated and uncomplexed human annexin A2 (PDB ID 
2HYW) was used, and it has 30 amino acids in the N-terminal region, which were not 
visible in the structure [73]. In global docking, most of the SP40 peptide poses were placed 
between the groove of domains I and II, domains II and III, and domains III and IV, as 
shown in Figure 2G. The first five top-scoring poses that were used for local docking were 
located in the groove between domains I and II and domains III and IV.  
Human tryptophanyl-tRNA synthetases (hTrpRS) are enzymes in the human body 
that exist in two different cytoplasmic and mitochondrial forms. Cytoplasmic hTrpRS cat-
alyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by interferons 
which are signaling proteins made and released by host cells in response to the presence 
of several viruses [74]. The 3D structure of hTrpRS comprises three domains: a N-terminal 
domain up to residue 150, a Rossmann fold (RF) catalytic domain from residues 151–362 
and 453–471 and a C-terminal domain from residues 363–452. The catalytic active site is 
located in a deep pocket of the RF domain and is surrounded by several conserved struc-
tural elements, including the KMSAS loop (the connecting loop between strand β9 and 
helix α16), the HVGH motif (helix α7) and the AIDQ motif (helix α15). The substrate-
binding pocket comprises the Trp-binding site and the ATP-binding site. The anticodon-
binding site is placed at the tip of the C-terminal domain (residues 479–495) [75]. Yeung 
et al. [24] discovered hTrpRS as an IFN-γ-inducible EV-A71 cellular entry factor by using 
genome-wide RNAi library screening. The role of hTrpRS in facilitating EV-A71 entry and 
infectivity was confirmed by virus attachment, in vitro pulldown, antibody/antigen block-
ing, and CRISPR/Cas9-mediated deletion. RD cells with the hTrpRS knockdown could be 
protected to induce CPE in the presence of EV-A71 and reduced viral replication com-
pared to the control wild-type RD cells. The 3D structure of hTrpRS with the PDB ID 2QUJ 
used in this study contained 471 amino acids. The 87 residues of the N-terminal region of 
the protein is invisible in the structure. The global docking showed that majority of the 
SP40 peptide poses were placed close to the catalytic domain, which is responsible for the 
aminoacylation of tRNA(trp) with tryptophan (Figure 2H). However, the top-scoring 
SP40 peptide pose was located at the surface between the N and C terminals and catalytic 
domains. There is doubt that the catalytic domain is involved in EV-A71 attachment or 
entry of the virus to the cell. However, in local docking, all the five top-scoring poses of 
HPEPDOCK were used for further evaluations.  
The cell cytoskeletons are made up of microfilaments, microtubules and intermediate 
filaments (IF). Vimentin is a type III intermediate filament (IF) protein [76] that maintains 
the cell shape, is responsible for the integrity of the cytoplasm and stabilizes the cytoskel-
etal interactions. Vimentin is expressed in leukocytes, fibroblasts and endothelial cells of 
blood vessels. It is also expressed on the cell surface which plays a role in the attachment 
of several pathogens [77-80]. Du et al. [25] reported that vimentin could facilitate EV-A71 
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attachment to the cell. Pull-down assay proved that there was a direct binding of VP1 of 
EV-A71 to the vimentin receptor. Besides, using soluble vimentin, anti-vimentin antibody, 
and knockdown of vimentin expression by RNA interference (RNAi) also showed a re-
duction in EV-A71 infection. A combined treatment of U251 cells with anti-vimentin anti-
body and anti-SCARB2 antibody was found to be more effective in inhibiting EV-A71 in-
fection. Pull-down assay involving VP1 and truncated fragments of vimentin showed that 
N-terminal amino acids 1 to 56 of vimentin contained the domain that was directly re-
sponsible for the specific binding to VP1. Vimentin self-assembles into a dimer that later 
forms high-order structures, including tetramers and octamers. However, the details of 
intermediate filament assembly at crystallographic resolutions are limited to the tetram-
eric form. The crystal structure of vimentin that was used in this study has been deposited 
in the protein data bank with PDB ID 5WHF, which is a fragment of a vimentin rod-
shaped domain (coil 1B) with a dimer of tetramers in the asymmetric unit. Coil 1B in the 
crystal is in an infinitely high-order filamentous assembly state, in which the tetramers 
are packed against each other laterally in an antiparallel fashion across the crystal lattice 
[81]. Analysis of the global docking of SP40 peptide with vimentin showed that most of 
the SP40 peptide poses were covering the coil 1B in the middle and the N-terminal areas 
(Figure 2I). Most of the five top-scoring poses were close to the N-terminal part and was 
placed on the curved side of the coil 1B, which all used for the local docking study. 
Human prohibitin 2 (PHB2) contains 299 amino acids and it is expressed in cell com-
partments, such as mitochondria, nucleus and plasma membrane. Mitochondria and nu-
cleus prohibitin modulate a variety of signaling pathways controlling cell survival, me-
tabolism and inflammation [82]. The interaction of prohibitin 2 (PHB2) with the C-termi-
nal region of VP1 of EV-A71 was reported to induce autophagy. PHB2 knockdown led to 
a reduction in EV-A71 replication, viral particle release, viral protein synthesis and the 
inhibition of autophagy [83]. The available 3D structure of PHB2 in the protein database 
is the heptad repeat (HR) region of the protein from amino acids 188 to 265 with PDB ID 
6IQE that comprises a dimeric, anti-parallel coil–coil [84]. The global docking study 
showed that most of the SP40 peptide poses were located in the middle of the protein close 
to the N-terminal region of the 3D structure (Figure 2J). However, the first five top-scoring 
poses were very close to the N-terminal region of the protein that was used for local dock-
ing. 
PSGL-1 is a sialomucin leukocyte membrane protein, containing 428 amino acids that 
functions as a high-affinity counter-receptor for the cell adhesion molecules P-, E- and L-
selectins [85-87]. PSGL-1 is expressed by lymph node dendritic cells and macrophages in 
the intestinal mucosa [86]. It plays a significant role in trafficking the leukocytes during 
inflammation by tethering them to the sites of acute inflammation. The sulfation of the 
three tyrosine residues at positions 46, 48 and 51, near the N-terminal of PSGL-1, are im-
portant for EV-A71 binding. However, PSGL-1 functions as a receptor for only certain EV-
A71 strains. These criteria are dependent on the presence of the amino acid 145 in VP1 of 
EV-A71, which is either glycine or glutamic acid and defines PSGL-1 binding or non-bind-
ing to the EV-A71 strains. Sequence analysis of EV-A71 showed that around 80% of strains 
are not binding to PSGL-1. The cytopathic effects mediated by PSGL-1 binding to EV-A71 
could take a longer time (a few days) to be observed in the infected cells compared to EV-
A71 that used the SCRB2 receptor. So far, there is no 3D protein structure of PSGL-1 that 
could be used for molecular docking. PSI blast showed that there is no close structure to 
the PSGL-1 amino acid sequence for PSGL-1structure prediction. Therefore, PSGL-1 was 
not included in the molecular docking analysis.  
Heparan sulfate (HS) is a polydisperse linear polymer comprising alternate repeating 
disaccharide units of N-acetylated or N-sulfated glucosamine and glucuronic acid or idu-
ronic acid joined by (1–4) glycosidic linkage [88] that are highly negatively charged due 
to the sulfate groups. Tan et al. [19] showed that inhibiting the interaction between HS 
and EV-A71 by the preincubation of the virus with heparin or protecting the RD cells by 
preincubating the cells with poly-D-lysine could significantly abolish EV-A71 infection. 
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Treating the cells with heparinase I, II, and III could reduce EV-A71 binding to the surface 
of RD cells. In addition, blocking the biosynthesis of HS by sodium chlorate or knockdown 
of N-deacetylases/N-sulfotransferase-1 and exostosin-1 could reduce EV-A71 infection. 
However, HS was not expressed by EV-A71 infected cells that had high levels of SCARB2 
expression, indicating that HS did not participate in the replication or dissemination of 
the virus in vivo [30]. Since HS is a polydisperse linear polymer and cannot be analyzed 
by HPEPDOCK, HS was not included in the molecular docking analysis.  
Prior to local docking, five top-scoring models generated from HPEPDOCK for each 
of the receptors were uploaded to the FelxPepDock server for the high-resolution refine-
ment of the protein–peptide complexes. Several studies showed that FelxPepDock enables 
one to obtain the sub-Angstrom quality of the protein–peptide structure [89,90]. The top-
scoring generated models were energy minimized and used for local docking.  
2.2. Local Docking to Identify the Interaction Restraints of Cellular Receptors  
The process of identifying which receptor(s) are most likely to interact favorably with 
the SP40 peptide is scored using GOLD. Based on the global docking results, five top-
scoring complexes were selected to study the interaction of each receptor with the SP40 
peptide. For each receptor-SP40 peptide complex, 150 models were generated that were 
ranked based on GoldScore fitness. The generated results by GOLD for the best score of 
five top models were presented in Figure 3. In GOLD analysis, the higher fitness repre-
sented the higher affinity of the ligand to bind to the receptor. Based on the result, nucle-
olin demonstrated highest fitness score (125.3) followed by annexin A2 (113.5) and 
SCARB2(110.9). Only one SP40 peptide complex model with vimentin showed a high 
score (109.2) and the rest were of lower scores (55 to 79.2) while the five clustered models 
of human tryptophanyl-tRNA synthetase (hTrpRS) presented scores ranging from 93.0 to 
108.5. The reset of receptors showed scattered scores which could indicate the lack of abil-
ity to bind to the SP40 peptide. Therefore, the docked complex of SP40 peptide and nucle-
olin, annexin A2, SCARB2 and hTrpRS were analyzed in detail in this study by Discovery 
studio software.  
 
Figure 3. Docking scores (Goldscore) of five top models of receptor-SP40 peptide complexes for each receptor generated 
by GOLD analysis. 
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Nucleolin displayed higher fitness score when the SP40 peptide was docked to the 
area between its two RNA binding domains (RBDs). The binding pose of the SP40 peptide 
on the nucleolin receptor is shown in Figure 4A, while its interactions with the amino acid 
residues of the receptor are shown in Figure 4B. Table 1 shows the residues involved and 
the type of interactions between nucleolin and SP40 peptide. In the docked complex, the 
two RBDs and the linker interacted extensively with the SP40 peptide, 11 amino acids of 
RBD1 (Pro4, Asn9, Phe11, , Asn14, Phe17, Arg43Lys49, Phe50, Tyr52, Lys78 and Glu80), 7 
amino acids of RBD2 (Lys99, Asn100, Tyr103, Lys128, Ile132, Ser161 and , Tyr163, ) and 1 
amino acid of the linker (Lys81) mediated interactions with the SP40 peptide. In total, 
there were 1 salt bridge, 3 electrostatic interactions, 11 hydrogen bonds, 2 sulfur interac-
tions and 10 hydrophobic interactions found between nucleolin and the SP40 peptide. 
Among the 15 amino acids of SP40 peptide, 2 amino acids acted as hydrogen bond donors 
(Arg3, and Thr10), 5 amino acids acted as hydrogen bond acceptors (Gln1, Glu7, Leu8, 
Met12 and Asp15) and 6 amino acids were both hydrogen bond donors and acceptors 
(Met2, Arg4, Lys5, Val6, Phe9 and Arg13). Amino acids Tyr11 and Phe14 of SP40 peptide 




Figure 4. Analysis of interactions between the SP40 peptide with nucleolin. (A) The binding pose of SP40 peptide on 
nucleolin receptor, with SP40 peptide being placed between the RNA binding (RBD) domains of nucleolin. (B) Residues 
in nucleolin involved in interactions with the SP40 peptide. Residues in the target receptors are shown as lines, while 
residues in the SP40 peptide are shown in sticks. Salt bridge and electrostatic interactions are in orange color, the conven-
tional hydrogen bonds are shown in green dash line, carbon hydrogen bonds are in light green color, sulfur and hydro-
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Table 1. Residues in nucleolin involved in interactions with the SP40 peptide. 
No H-Donor residue Position H-Acceptor residue Position Distance Type of interaction 
1 LYS128 HZ2 ASP15 OD1 2.13 Salt Bridge 
2 LYS49 NZ GLU7 OE2 5.21 Electrostatic 
3 LYS78 NZ GLU7 OE2 4.44 Electrostatic 
4 LYS5 NZ GLU80 OE1 4.91 Electrostatic 
5 ARG43 HH21 GLN1 OE1 2.55 Conventional hydrogen bond 
6 LYS99 HZ1 ARG4 O 2.76 Conventional hydrogen bond 
7 ARG3 H13 TYR52 OH 1.72 Conventional hydrogen bond 
8 LYS5 H14 LYS81 O 1.79 Conventional hydrogen bond 
9 PHE9 H14 ASN100 OD1 3.02 Conventional hydrogen bond 
10 ARG13 H14 ASN14 OD1 2.65 Conventional hydrogen bond 
11 ARG13 H14 ASN14 OD1 2.54 Conventional hydrogen bond 
12 ARG4 H14 TYR163 OH 1.92 Carbon hydrogen bond 
13 THR10 H13 ASN100 OD1 2.57 Carbon hydrogen bond 
14 ARG13 H14 TYR103 OH 2.15 Carbon hydrogen bond 
15 MET2 SD ASN9 ND2 3.23 Sulfur-X 
16 SER161 HG PHE9 Pi-Orbitals 3.22 Pi-Donor Hydrogen Bond 
17 MET2 SD TYR52 Pi-Orbitals 4.37 Pi-Sulfur 
18 PRO4 Alkyl MET2 Alkyl 4.93 Hydrophobic-Alkyl 
19 LYS99 Alkyl VAL6 Alkyl 5.29 Hydrophobic-Alkyl 
20 VAL6 Alkyl ILE132 Alkyl 4.79 Hydrophobic-Alkyl 
21 PHE11 Pi-Orbitals LYS5 Alkyl 4.42 Hydrophobic-Pi-Alkyl 
22 PHE11 Pi-Orbitals VAL6 Alkyl 4.93 Hydrophobic-Pi-Alkyl 
23 PHE17 Pi-Orbitals MET12 Alkyl 5.19 Hydrophobic-Pi-Alkyl 
24 PHE17 Pi-Orbitals ARG13 Alkyl 4.25 Hydrophobic-Pi-Alkyl 
25 PHE50 Pi-Orbitals LEU8 Alkyl 5.11 Hydrophobic-Pi-Alkyl 
26 TYR103 Pi-Orbitals ARG13 Alkyl 5.11 Hydrophobic-Pi-Alkyl 
27 TYR163 Pi-Orbitals ARG4 Alkyl 5.28 Hydrophobic-Pi-Alkyl 
SP40 peptide residues involved in interactions are in bold and in italic. 
Alanine scanning of the SP40 peptide showed that replacing the amino acids Arg3, 
Arg4, Lys5, Met12 and Arg13 with Ala residue could decrease 60 to 80% inhibitory effects 
of the SP40 peptide [31]. Analyzing the docked complex of SP40 peptide with nucleolin 
showed that Arg3 is interacting with Tyr52 to form a hydrogen bond and Arg 4 is inter-
acting with Lys99 and Tyr163 to form two hydrogen bonds and with Tyr163 to form one 
hydrophobic interaction. Lys5 is involved in 3 electrostatic, hydrogen bond and hydro-
phobic interactions with Glu80, Lys81 and Phe11, respectively. Aside from this, Met12 
formed one hydrophobic interaction with Phe17 while Arg13 formed three hydrogen 
bonds and two hydrophobic interactions. 
Tan et al. [31] showed that the SP40 peptide does not bind to EV-A71 and it is not 
virucidal to EV-71 viral particles [31]. Since pre-incubation of the RD cell with the SP40 
peptide prior to EV-A71 infection showed around 90% inhibitory effects on plaque for-
mation and RNA copy number reduction in EV-A71 when compared to the addition of 
SP40 peptide during post-infection where very minor inhibition of viral infectivity was 
observed (Unpublished observation), indicating that SP40 peptide was interacting with 
cell receptor and preventing EV-A71 at the attachment or entry-stage. However, Su et al. 
[21] showed that the knockdown of cell surface nucleolin significantly decreased EV-A71 
infection and RNA production in human cells. The EV-A71 RNA levels were decreased 
by 25% and 45% in the nucleolin-knockdown cells at 3 and 6 h post-infection, respectively.  
The SP40 peptide had demonstrated broad antiviral activities against EV-A71, CV-
A16 and poliovirus type 1 in RD cell cultures [31]. Meanwhile, Waggoner and Sarnow 
(1998) showed nucleocytoplasmic relocalization of nucleolin into the cytoplasm following 
poliovirus infection [91]. Izumi et al. [47] showed that nucleolin stimulated viral IRES-
mediated translation both in vitro and in vivo. A nucleolin mutant lacking the RBD1 could 
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not perform IRES-mediated translation in vitro, which highlighted the role of RBD1 in 
viral protein translation [47]. Since poliovirus and EV-A71 both use viral IRES-mediated 
translation, nucleolin might have the same function in the translation of EV-A71. Hence, 
blocking nucleolin using the SP40 peptide might inhibit the translation of EV-A71. As the 
entire structure of nucleolin is not available in the protein database, it is not possible to 
predict the interaction of SP40 peptide with the acidic N-terminal domain or the C-termi-
nal RGG rich tail of nucleolin which could be involved in the attachment of EV-A71 to 
nucleolin.  
Annexin A2 in local docking analysis with the SP40 peptide as a ligand showed the 
second-best fitness GoldScore compare to the other cellular receptors. The complexes of 
the SP40 peptide compared to different regions of annexin 2 in 5 different models were 
studied. The best Gold-score belongs to the SP40 peptide docked in the cavity area be-
tween domains II, III and IV on the opposite side of the N- and C-terminals regions (Figure 
5A). The SP40 peptide interactions with the amino acid residues of the receptor are shown 
in Figure 5B. Post docking analysis of SP40 peptide-annexin A2 complex revealed 26 in-
teractions comprising 4 salt bridges, 6 electrostatic and 11 hydrogen bonds, 1Pi-lone pair 
and 4 hydrophobic interactions between the SP40 peptide and annexin A2 receptor (Table 
2). In the docked complex, three domains of annexin A2 vastly interacted with the SP40 
peptide, 3 amino acids of domain II (Ther122, Asp123 and Glu124), 6 amino acids of do-
main III (Lys232, Asp238, Leu240, Glu241, Arg244, and Gln260) and 7 amino acids of do-
main IV (Leu267, Thr282, Arg283, Asp284, Lys285 and Lys309) mediated interactions with 
the SP40 peptide. Among 15 amino acids of the SP40 peptide, 3 amino acids acted as hy-
drogen bond donors (Arg3, Arg4 and Lys5,), 6 amino acids acted as hydrogen bond ac-
ceptors (Gln1, Met2, Glu7, Tyr11, Met12 and Asp15), 2 amino acids were both hydrogen 
bond donors and acceptors (Arg13 and Phe14) and 4 amino acids showed no interactions 
(Val6,Leu8, Phe9, and Thr10). Arg 3 formed two electrostatic interactions and Arg4 
formed two hydrogen bonds with amino acids in domains III and IV, respectively. Lys5, 
and Asp15 also mediated two salt bridges, two electrostatic interactions with amino acids 
in domain III and IV. Glu7 formed one salt bridge and one hydrogen bond with amino 
acids in domain III while Arg13 made one salt bridge, five hydrogen bonds and two elec-
trostatic interactions with amino acids in domain II and III. 
(A) (B) 
Figure 5. Analysis of interactions between SP40 peptide with annexin A2. (A) The binding pose of SP40 peptide on annexin 
A2 receptor. (B) Residues in annexin A2 involved in interactions with the SP40 peptide. Residues in the target receptors 
are shown as lines, while residues in the SP40 peptide are shown in sticks. Salt bridge and electrostatic interactions are in 
orange color, the conventional hydrogen bonds are shown in green dash line, carbon–hydrogen bonds are in light green 
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Table 2. Residues in annexin A2 involved in interactions with the SP40 peptide. 
No H-Donor Residue Position H-Acceptor Residue Position Distance Type of Interaction 
1 ARG244 HH21 GLU7 OE2 2.86 Salt Bridge 
2 LYS285 HZ2 ASP15 OXT 3.11 Salt Bridge 
3 LYS5 H25 ASP238 OD1 2.63 Salt Bridge 
4 ARG13 H26 GLU124 OE1 2.92 Salt Bridge 
5 LYS285 NZ ASP15 O 4.34 Electrostatic 
6 ARG3 NH1 ASP238 OD1 5.51 Electrostatic 
7 ARG3 NH2 GLU241 OE1 5.26 Electrostatic 
8 LYS5 NZ GLU241 OE1 4.29 Electrostatic 
9 ARG13 NH1 ASP123 OD1 3.57 Electrostatic 
10 ARG13 NH2 ASP123 OD2 4.28 Electrostatic 
11 LYS232 HZ1 GLN1 OE1 2.21 Conventional hydrogen bond 
12 GLN260 HE21 GLU7 OE1 1.81 Conventional hydrogen bond 
13 LYS285 HZ3 PHE14 O 2.59 Conventional hydrogen bond 
14 ARG4 H25 LYS309 O 2.71 Conventional hydrogen bond 
15 ARG4 H25 LYS309 O 1.53 Conventional hydrogen bond 
16 ARG13 H26 THR122 O 2.50 Conventional hydrogen bond 
17 ARG283 HD1 ARG13 O 2.96 Carbon hydrogen bond 
18 ARG283 HD2 TYR11 O 2.11 Carbon hydrogen bond 
19 LYS285 HE2 PHE14 O 2.56 Carbon hydrogen bond 
20 ARG13 H26 ASP123 OD1 2.98 Carbon hydrogen bond 
21 ASP284 H PHE14 Pi-Orbitals 2.99 Pi-Donor hydrogen bond 
22 THR282 O PHE14 Pi-Orbitals 2.77 Pi-Lone Pair 
23 LEU267 Alkyl MET2 Alkyl 4.68 Hydrophobic-Alkyl 
24 ARG283 Alkyl MET12 Alkyl 4.85 Hydrophobic-Alkyl 
25 LYS5 Alkyl LEU240 Alkyl 5.43 Hydrophobic-Alkyl 
26 PHE14 Pi-Orbitals ARG283 Alkyl 5.11 Hydrophobic-Pi-Alkyl 
SP40 peptide residues involved in interactions are in bold and in italics. 
The overall annexin molecule is planar and curved with opposing concave and con-
vex surfaces. The concave face of the protein faces the cytosol and contains both the N-
terminal and C-terminal domains. The convex surface lies along the plane of the phospho-
lipid membrane and also contains the interhelical loops and seven Ca2+-binding sites. The 
common heparin-binding site is situated at the convex face of domain IV of annexin A2. 
At this site, annexin A2 binds up to five sugar residues from the nonreducing end of the 
oligosaccharide. One of these Ca2+-binding sites lies between the IV-AB (Gly279– Arg283) 
and IV-DE (Thr322–Tyr326, including the N-terminal end of helix E of domain IV) loops 
in domain IV of annexin A2, where it participates in heparin binding. For heparin-binding 
at this site, main-chain and side-chain nitrogen atoms and two calcium ions play im-
portant roles in the binding [73]. The IV-AB loop conformation stabilization is through the 
coordination of binding to the Ca2+ ion and it provides a pre-formed binding surface suit-
able for oligosaccharide residue. In addition to the protein-bound Ca2+ ion, heparin inter-
acts with annexin A2 through polar interactions, mostly between its sulfated oxygen at-
oms and the nitrogen atoms from the IV-AB and IV-DE loops residues of annexin A2. 
Interestingly, SP40 peptide binds to the residues in the IV-AB loop (Thr282 and Arg283) 
of domain IV by two hydrogen bonds, two hydrophobic and one Pi-lone pair interactions 
which could alter the conformation of the IV-AB and disrupt the Ca2+ binding and subse-
quently prevent the heparin-binding. 
Furthermore, the nonreducing end of the oligosaccharide binds at the IV-AB loop, 
consistent with a possible physiological recognition site for the nonreducing end of the 
free heparin polymer or the heparan sulfate (HS) glycosaminoglycan chain attached to a 
proteoglycan [73]. The binding of SP40 peptide to domain IV of annexin might prevent 
the covalent attachment of HS to core proteins such as annexin A2, which could inhibit 
the attachment or entry of the EV-A71 to the target cell through HS. 
Local docking analysis of the SP40 peptide under the head region of SCARB2 showed 
a better fitness score compared to the docking of the peptide to the large anti-parallel β-
barrel in the middle domain (Model 5, Figure 3). SCARB2 was the third receptor that 
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showed a high score to bind to the SP40 peptide. Local docking analysis of the concavity 
under the head domain of SCARB2 exhibited a higher score compared to the pose that 
SP40 peptide extensively binds to the head domain (Model 3, Figure 3). The binding pose 
of the SP40 peptide on the SCARB2 receptor is shown in Figure 6A and SP40 peptide in-
teractions with the amino acid residues of the receptor are presented in Figure 6B. Analy-
sis of the docked complex of SP40 peptide-SCARB2 showed that six amino acids of the 
head region (Glu145, Trp146, Gln148, Asp194, Ser196 and Tyr198) and eight amino acids 
of the middle region (Phe199, Gly200, Tyr203, Glu204, Pro314, Ile328, Gly332 and Tyr388) 
of SCARB2 interacted with SP40 peptide (Table 3).  
 
(A) (B) 
Figure 6. Analysis of interactions between SP40 peptide with SCARB2. (A) The binding pose of SP40 peptide on SCARB2 
receptor. (B) Residues in SCARB2 involved in interactions with the SP40 peptide. Residues in the target receptors are 
shown as lines, while residues in the SP40 peptide are shown in sticks. Salt bridge is in orange color, the conventional 
hydrogen bonds are shown in green dash line, carbon hydrogen bonds are in light green color, electrostatic interaction is 
in yellow and hydrophobic interaction is in purple color. 
Table 3. Residues in SCARB2 involved in interactions with the SP40 peptide. 
No H-Donor Residue Position H-Acceptor Residue Position Distance Type of Interaction 
1 LYS5 H31 ASP194 OD2 1.72 Salt Bridge 
2 TYR388 HH ASP15 OD1 2.21 Conventional hydrogen bond 
3 GLN1 H31 GLU204 OE2 2.21 Conventional hydrogen bond 
4 ARG3 H31 GLY200 O 1.70 Conventional hydrogen bond 
5 ARG3 H31 GLY200 O 2.25 Conventional hydrogen bond 
6 ARG4 H31 SER196 O 2.83 Conventional hydrogen bond 
7 ARG4 H31 TYR198 O 2.39 Conventional hydrogen bond 
8 THR10 H32 GLY332 O 2.36 Conventional hydrogen bond 
9 ARG13 H31 GLN148 OE1 2.72 Conventional hydrogen bond 
10 ARG13 H32 GLN148 O 2.81 Conventional hydrogen bond 
11 ARG13 H32 GLN148 OE1 1.64 Conventional hydrogen bond 
12 ARG3 H31 GLU204 OE1 1.96 Carbon hydrogen bond 
13 ARG3 H31 TYR203 O 2.61 Carbon hydrogen bond 
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15 GLU145 OE1 PHE14 Pi-Orbitals 4.79 Electrostatic-Pi-Anion 
16 TRP146 Pi-Orbitals PHE9 Pi-Orbitals 3.70 Hydrophobic-Pi-Pi Stacked 
17 TRP146 Pi-Orbitals PHE9 Pi-Orbitals 3.60 Hydrophobic-Pi-Pi Stacked 
18 PRO314 Alkyl MET12 Alkyl 5.37 Hydrophobic-Alkyl 
19 ILE328 Alkyl LEU8 Alkyl 4.88 Hydrophobic-Alkyl 
SP40 peptide residues involved in interactions are in bold and in italics. 
Post docking analysis of the complex of SP40 peptide-SCARB2 revealed 19 interac-
tions, 1 salt bridge, 12 hydrogen bonds, 2 electrostatic Pi- interactions and 4 hydrophobic 
interactions between the SP40 peptide and SCARB2 receptor. Among 15 amino acids of 
SP40 peptide, six amino acids acted as hydrogen bond donors (Gln1, Arg3, Arg4, Lys5, 
Thr10and Arg13) and five amino acids acted as hydrogen bond acceptors (Leu8, Phe9, 
Met12, Phe14 and Asp15). Furthermore, four amino acids of SP40 peptide (Met2, Val6, 
Glu7 and Tyr11) did not form any interaction with SCARB2. Arg3 of SP40 peptide formed 
four hydrogen bonds and an electrostatic- Pi-Cation interaction while Arg4 formed two 
hydrogen bonds. Lys5 mediated a salt bridge and Gln1 and Arg 13 were involved in one 
and three hydrogen bonds with SCARB2, respectively. Asp15 as an acceptor residue 
formed one hydrogen bond while Leu8, Phe 9 and Met12 were involved in hydrophobic 
interactions and Phe 14 formed an electrostatic -Pi anion interaction.  
In the 3D structure of SCARB2, α-helix 4 (amino acids 138–146) and α-helix 5 (amino 
acids 149–163) are linked by Ser147 and Gln148. The α-helix 7 (amino acids 182–189) is 
linked to the middle domain by amino acids 190–198. These helices were reported to bind 
to the GH loop of VP1 and the EF loop of VP2 capsid proteins of EV-A71 [60]. Interest-
ingly, the analysis of the SP40 peptide-SCARB2 complex displayed that Glu145 and 
Trp146of α-helix 4 acted as a hydrogen donor residue and formed one electrostatic and 
two hydrophobic interactions with Phe14 and Phe9 of SP40 peptide. Additionally, three 
amino acids (Asp194, Ser196 and Tyr198) that linked the head domain helices to the mid-
dle domain formed one salt bridge and five hydrogen bonds with SP40 peptide. Binding 
of SP40 peptide to the α-helix 4 and linker of the α-helix 7 might inhibit the binding of EV-
A71 to SCARB2 and prevent virus entry into the cells. The interaction of the SP40 peptide 
to the head and middle regions of the SCARB2 might change the structural conformation 
of the receptor. This structural alteration of the receptor might prevent the attachment of 
the receptor to the capsid VP1 protein of EV-A71 and subsequently, reduced the infection 
rate of the virus.  
The local molecular docking of five top-scoring complexes of human tryptophanyl-
tRNA synthetases (hTrpRS) with SP40 peptide had revealed the fourth highest fitness 
score among the other analyzed cellular receptors (Figure 3) when the SP40 peptide was 
docked to the cavity between N-terminal and C-terminal domains and between N-termi-
nal and the catalytic domain of hTrpRS (supplementary Figure1A). The binding pose of 
the SP40 peptide on the hTrpRS receptor is shown in Figure 7A, while its interactions with 
the amino acid residues of the receptor are presented in Figure 7B. The residues involved 
and the type of interactions between hTrpRS and SP40 peptide are shown in Table 4. In 
the docked complex, the hTrpRS interacted with the SP40 peptide with the formation of 
12 hydrogen bonds, 3 electrostatic, 1 Pi-cation and 6 hydrophobic interactions. The amino 
acids of hTrpRS that mediated the interaction with SP40 peptide belonged to the N-termi-
nal domain (Arg122, Ala123 and Tyr150) and catalytic domain (Glu151, Lys153, Lys154, 
Pro155, Phe468, Asp469 and His472).  





Figure 7. Analysis of interactions between SP40 peptide with human tryptophanyl-tRNA synthetase (hTrpRS). (A) The 
binding pose of SP40 peptide on hTrpRS receptor. (B) Residues in hTrpRS involved in interactions with the SP40 peptide. 
Residues in the target receptors are shown as lines, while residues in the SP40 peptide are shown in sticks. Electrostatic 
interactions are in orange color, the conventional hydrogen bonds are shown in green dash line, carbon hydrogen bonds 
are in light green color and hydrophobic interactions are in pink color. 
Table 4. Residues in human tryptophanyl-tRNA synthetase involved in interactions with the SP40 peptide. 
No H-Donor Residue Position H-Acceptor Residue Position Distance Type of Interaction 
1 LYS154 NZ ASP15 O 4.41 Electrostatic 
2 ARG3 NH2 GLU151 OE1 4.31 Electrostatic 
3 ARG13 NH1 ASP302 OD2 5.10 Electrostatic 
4 TYR150 HH ARG3 O 2.75 Conventional Hydrogen Bond 
5 ASP469 H GLU7 OE2 2.20 Conventional Hydrogen Bond 
6 GLN1 H30 ARG122 O 2.44 Conventional Hydrogen Bond 
7 GLN1 H32 ARG122 O 3.02 Conventional Hydrogen Bond 
8 ARG3 H31 GLU151 O 3.05 Conventional Hydrogen Bond 
9 PHE14 H32 ASP302 OD2 1.54 Conventional Hydrogen Bond 
10 ASP15 H32 ASP302 OD2 2.77 Conventional Hydrogen Bond 
11 LYS154 HE1 PHE14 O 2.84 Carbon Hydrogen Bond 
12 PHE468 HA GLU7 OE2 2.93 Carbon Hydrogen Bond 
13 MET2 H30 ALA123 O 3.10 Carbon Hydrogen Bond 
14 ARG3 H31 GLU151 O 2.88 Carbon Hydrogen Bond 
15 ARG13 H32 ASP302 OD2 2.48 Carbon Hydrogen Bond 
16 LYS5 NZ PHE468 Pi-Orbitals 4.46 Electrostatic-Pi-Cation 
17 LYS153 Alkyl VAL6 Alkyl 4.77 Hydrophobic-Alkyl 
18 ARG4 Alkyl LYS153 Alkyl 5.48 Hydrophobic-Alkyl 
19 TYR150 Pi-Orbitals ARG3 Alkyl 4.37 Hydrophobic-Pi-Alkyl 
20 HIS472 Pi-Orbitals MET12 Alkyl 4.19 Hydrophobic-Pi-Alkyl 
21 PHE9 Pi-Orbitals PRO155 Alkyl 4.10 Hydrophobic-Pi-Alkyl 
22 PHE14 Pi-Orbitals LYS154 Alkyl 4.47 Hydrophobic-Pi-Alkyl 
SP40 peptide residues involved in interactions are in bold and in italic. 
Moreover, six amino acids of SP40 peptide are interacting with hTrpRS, and they 
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Glu7 and Met12acted as hydrogen bond acceptors and Arg3, Phe14 and Asp15 were both 
hydrogen bond donors and acceptors. Arg3 formed three hydrogen bonds with Tyr150 
and Glu151 and one electrostatic and one hydrophobic interaction with Glu151 and 
Tyr150, respectively. Arg122 and Ala123 of the N-terminal domain of hTrpRS mediated 
three hydrogen bonds with Gln1 and Met2 of SP40 peptide. Glu7, Arg13 Phe14, Asp15 
formed six hydrogen bonds with amino acids in the catalytic domain of hTrpRS..  
The hTrpRS is involved in aminoacylation reaction in which the tRNA acceptor arm 
interacted with helix α1′ (amino acids 100–108) of the N-terminal domain and helices α6 
(amino acids 259–265) and α9 (amino acids 321–329) of the catalytic domain. Helix α1′ 
acted as a platform at the entrance to the catalytic active site to hold the tRNA 3′ end. The 
3′ end anticodon took a sharp turn to enter into the catalytic active site with a deformed 
conformation. The nucleotide base interacted with three residues (Asp99, Lys102 and 
Arg106) of helix α1′ [92]. Conformational changes caused by binding to the SP40 peptide 
might affect the aminoacylation reaction. 
As there is no mechanism of action study related to the attachment or entry of EV-
A71 through the hTrpRS receptor, it would be difficult to justify the docking result. How-
ever, if EV-A71 used the tRNA acceptor arm to interact with the N-terminal for attachment 
or entry, it would be affected by the presence of SP40 peptide which could bind to Arg122 
and Ala123 of helix α2′ and change the conformation of the hTrpRS receptor.  
The finding of the molecular inhibition mechanism of the SP40 peptide was further 
verified through receptor-blocking experiments. Seven receptors (nucleolin, annexin A2, 
PSGL-1, vimentin, heparan sulfate, galectin-1andSCARB2) of EV-A71 expressed in RD 
cells were blocked by the respective anti-receptor antibodies and their inhibitory effects 
in the presence and absence of SP40 peptide were analyzed. 
2.3. SP40 Peptide Worked Synergistically with Anti-Receptor Antibodies 
Attachment or entry of EV-A71 to seven receptors of EV-A71 were selectively 
blocked with their respective antibodies followed by L-SP40 peptide (100 µM) treatment. 
The results indicated that the L-SP40 peptide synergistically enhanced the inhibitory ef-
fects of antibodies to specific receptors when they were blocked with their respective an-
tibodies and subsequently incubated with the L-SP40 peptide. All the antibodies were 
used at the maximum concentration which was found to be non-cytotoxic. With the ex-
ception of annexin A2 at 10 µg/mL, all the other antibodies were used at 20 µg/mL.  
Anti-nucleolin and anti-annexin A2 receptors when blocked with their respective an-
tibodies exhibited the highest inhibition of EV-A71 infection at 92.88% and 89.55%, respec-
tively (Table 5). The residual viral infectivity exhibited by the virus was found to be sig-
nificantly lower than the untreated the antibodies against the other receptors (anti-vi-
mentin, anti-heparan sulfate, anti-PSGL virus control (Figure 8). Treatment with -1 and 
anti-galectin-1) were observed not to exhibit such high levels of viral inhibition when RD 
cells were treated with them. When SCARB2, a critical uncoating receptor of EV-A71 was 
blocked with an anti-SCARB2 antibody, the inhibition of viral infectivity was found to be 
51%. Similarly, antibodies against attachment receptors, such as heparan sulfate or galec-
tin-1 could only inhibit infectivity by 63.1% and 58.5%, respectively. Other anti-receptor 
antibodies, such as anti-vimentin and anti-PSGL-1 antibodies, were able to inhibit the in-
fectivity at 65.1% and 75.9%, respectively. The very high levels of inhibition of infectivity 
by anti-nucleolin and anti-annexin A2 antibodies indicated that these two receptors 
played very significant roles as receptors for EV-A71 interactions in comparison with the 
remaining receptors being evaluated. 
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Table 5. Comparison of reduction in viral infectivity after antibody treatments against specific 
receptors in the presence or absence of SP40 peptide. 
Antibody Treatment Inhibition of Viral Infec-tivity (%) 
Inhibition of Viral Infectivity with 
L-SP40 Peptide (%) 
Anti-nucleolin  92.88 ± 1.40 96.28 ± 0.72 
Anti-annexin A2 89.55 ± 1.85 92.87 ± 2.06 
Anti-PSGL-1 75.91 ± 11.38 88.56 ± 4.38 
Anti-vimentin 65.13 ± 10.91 96.46 ± 1.21 
Anti-heparan Sulfate 63.16 ± 7.49 98.2 ± 0.68 
Anti-galectin-1 58.5 ± 4.25 95.43 ± 1.90 
Anti-SCARB2 51.04 ± 1.81 99.54 ± 0.34 
PSGL-1: P-selectin glycoprotein ligand-1, SCARB2: human scavenger receptor class B member 2. 
Inhibition of EV-A71 infection by L-SP40 peptide (100 µM) was 89.55 ± 1.85. Infectivity was deter-
mined by plaque formation assay in Rhabdomyosarcoma (RD) cells. SD denotes standard devia-
tions ± SD. 
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Figure 8. Effects of L-SP40 peptide with specific anti-receptor antibodies on viral infectivity. RD cells were 
treated with antibodies targeting various receptors for 1 h followed by incubation with 100µM L-SP40 pep-
tide for 1 h. The L-SP40 peptide-treated cells were subsequently infected with EV-A71 (MOI = 0.1) for 1 h. 
Viral infectivity was determined by plaque assays. Error bars indicate the range of values obtained from 
three independent experiments (* p < 0.05, **p < 0.01, ns = non-significant analyzed by t-test). 
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Interestingly, when L-SP40 peptide was added to RD cells that were blocked by anti-
receptor antibodies, there was a significant increase in the inhibition of viral infectivity to 
more than 90% except for anti-PSGL-1, where the reduction was found to be 88.5%. When 
anti-annexin A2 and anti-nucleolin blocked cells were treated with L-SP40 peptide, the 
inhibition increased slightly from 89.5% to 92.87% and from 92.8 % to 96.28%, respectively. 
The maximum inhibition of infectivity (99.54 %) was observed when L-SP40 peptide was 
added to the SCARB2 receptor blocked with anti-SCARB2compared to all treatment 
groups. Blocking the other receptors with their respective antibodies, except for annexin 
A2, showed that the inhibitions of viral infectivity were lower than that achieved by anti-
nucleolin treatment. Therefore, when each of the receptors (except for nucleolin) were 
treated with their respective antibodies together with SP40 peptide, the unblocked nucle-
olin receptor was able to interact with SP40 peptide and this inhibition further contributed 
to the significant decrease in viral infectivity. 
However, since anti-nucleolin and anti-annexin A2 antibodies together with SP40 
peptide exhibited quite similar inhibition (96.3% versus 92.8%), it is possible to speculate 
that SP40 peptide could also bind to annexin A2. In cells treated with anti-nucleolin and 
SP40 peptide, the residual infectivity could be explained by EV-A71 interaction with other 
receptors that showed a low probability of binding with SP40 peptide such as human ga-
lectin and prohibitin (Figure 3). The results indicated that EV-A71 could use more than 
one receptor to attach and enter the RD cells because none of the receptor-specific anti-
bodies could provide complete inhibition of infectivity of EV-A71. However, blocking the 
nucleolin and annexin A2 receptor showed minimal residual infectivity at 7.12% and 
10.45%, respectively (Figure 8), indicating that these two receptors are more crucial for 
attachment and entry of EV-A71 strain 41 into the RD cells. Further decrease in residual 
infectivity was observed with the addition of L-SP40 peptide to the RD cells which were 
prior blocked with specific anti-receptor antibodies. Since peptide L-SP40 was demon-
strated to bind to nucleolin receptor, the above observations suggested that blocking of 
other receptors, such as SCARB2, heparin sulfate, vimentin and galectin-1 with their re-
spective antibodies, and the L-SP40 peptide simultaneously could be beneficial in achiev-
ing augmented inhibitions of EV-A71.  
It is interesting to note that despite blocking the nucleolin receptor, the virus was still 
able to enter the cells and replicate, albeit at low infectivity of 7.12%. This finding sug-
gested that EV-A71 could use more than one receptor to enter the cells and continue to 
replicate. The results were in agreement with the previous study by He et al. [23] who 
suggested that blocking or knockdown any of the receptors would not completely abolish 
the infection but would only decrease infection [23]. Our observations also indicated that 
antibody treatments to block specific receptors of EV-A71 did show a reduction in infec-
tivity such as treatment with anti-SCARB2 resulted in 49% residual infectivity but could 
not completely abolish infectivity. Hence, treatment directed towards a single attachment 
or entry receptor of EV-A71 with a specific antibody alone would not be a suitable option 
for receptors other than nucleolin and annexin A2.  
Interestingly, when the RD cells were blocked by anti-receptor antibodies and subse-
quently treated with L-SP40 peptide, a significant increase in inhibition of infectivity was 
observed. Remarkably, when the L-SP40 peptide was used in conjunction with the anti-
SCARB2 receptor antibody, 99.5% inhibition with less than 0.5% residual infectivity was 
observed. This observation indicated that blocking the SCARB2 (uncoating receptor) with 
an anti-SCARB2 antibody followed by treatment with L-SP40 peptide could significantly 
reduce the viral infectivity to only 0.46%. 
3. Materials and Methods 
3.1. Software used for Molecular Docking 
Docking studies were performed using three different software packages: 
HPEPDOCK (http://huanglab.phys.hust.edu.cn/hpepdock/) (accessed on 5 August 2021) 
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[35], FlexPepDock (http://flexpepdock.furmanlab.cs.huji.ac.il/) (accessed on 15 August 
2021) [45], GOLD Suite (Hermes 2020.3.0) [41] and YASARA v21.6.17 software 
(http://www.yasara.org/) used to energy minimized the 3D-structure of the receptors and 
receptor-SP40 peptide complexes. The SP40 peptide structure was modeled using the 
PEP-FOLD online server (https://bioserv.rpbs.univ-paris-diderot.fr/services/PEP-FOLD/) 
(accessed 2 March. 2021). All the cell receptors and peptide structures were energetically 
minimized using YASARA software and saved as a PDB file format. 
The molecular docking calculation and data analysis were performed on an Intel(R) 
Xeon(R) W-2135 CPU @ 3.70GHz- based machine running MS Windows 10 as an operat-
ing system. 
3.2. Preparation of Cell Receptors and SP40 Peptide 
The protein structures of the following receptors were retrieved from the Protein 
Data Bank (https://www.rcsb.org/) (accessed on 10th March, 2021): human galectin-1 
(PDB ID: 1GZW) with a resolution of 1.70 Å, nucleolin (PDB: 2KRR) (solution NMR), 
SCARB2 (PDB ID: 4F7B) with a resolution of 3.006 Å, fibronectin (PDB ID: 1FNF) with a 
resolution of 2.00 Å, human prohibitin (PHB) (PDB ID: 6IQE) with a resolution of 1.70 Å, 
human tryptophanyl-tRNA synthetase (PDB ID: 2QUJ) with a resolution of 2.42 Å, An-
nexin A2 (PDB ID: 2HYW) with a resolution of 2.10 Å, human cyclophilin (PDB ID: 
5KUW) with a resolution of 1.70 Å and vimentin (PDB ID: 5WHF) with a resolution of 
2.25 Å.  
The structure of dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin (DC-SIGN) was predicted by YASARA software (http://www.yasara.org/) 
based on default setting using 5 templates of the DC-SIGN retrieved from the PDB; crystal 
structures of DC-SIGN_CRD with PDB ID 1SL4 with a resolution of 1.55 Å, PDB ID 1SL5 
with a resolution of 1.80 Å, PDB ID 2IT5 with a resolution of 2.40 Å, PDB ID 2IT6 with a 
resolution of 1.95 Å and PDB ID 2XR6 with a resolution of 1.35 Å. Meanwhile, there is no 
available structure of PSGL-1 and sialic acid in the database.  
The docking was performed on one chain of all cell receptor structures. The struc-
tures were prepared using YASARA by removing the water molecules, ligands and he-
tatoms. The hydrogen atoms were added to the structure for optimization and it was en-
ergy minimized and saved in active pdb format files. 
The amino acid sequence of the SP40 peptide (QMRRKVELFTYMRFD) was submit-
ted to the PEP-FOLD online server to model the three-dimensional (3D) structure of the 
peptide. The predicted model of the SP40 peptide in the pdb format file was subjected to 
YASARA where hydrogen atoms were added, energy minimized and saved in the active 
pdb format file.  
3.2.1. Docking Procedure 
HPEPDOCK. In global docking, the pdb files of receptors and SP40 peptide were 
uploaded to http://huanglab.phys.hust.edu.cn/hpepdock/ server (accessed on 5th August, 
2021). Default values of all parameters were used. By default, the number of generated 
peptide conformations was set to 1000 in the webserver and the top 100 peptide binding 
models were selected. As no information about the binding site was provided, the sphere 
points (represent the negative images of the molecular shape generated by SPHGEN), 
covering the whole receptor, were clustered and used to represent the possible peptide 
binding positions on the receptor. Then, the putative peptide binding modes were glob-
ally sampled by matching the peptide atoms with the sphere points [93]. The modified 
version of MDock was used to dock the ensemble of peptide conformations against the 
whole receptors [94-95]. In HPEPDOCK, all of the sampled binding modes were ranked 
by an iterative knowledge-based scoring function. The sampled binding orientations were 
optimized by a SIMPLEX minimization algorithm guided by their binding energy scores, 
in which both the receptor and the peptide were treated as rigid bodies [96]. The final 100 
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docking models were provided and saved. The conformation poses of the cell receptor 
and the SP40 peptide were viewed by the PyMOL software. 
FlexPepDock. The refinement of the receptor-SP40 peptide complex was performed 
using FlexPepDock. The set of five top-scoring receptor-SP40 peptide complexes for each 
receptor from HPEPDOCK was selected, cleaned and energy minimized by YASARA. 
Then, the pdf file of the receptor-SP40 peptide complex was uploaded to http://flex-
pepdock.furmanlab.cs.huji.ac.il/ server (accessed on 15th August, 2021). The server docked 
the peptide starting from initial conformation as uploaded in the receptor-peptide com-
plex pdf file. By default, the server was used to perform 100 simulations in full-atom mode 
and 100 simulations that included a preceding low-resolution centroid-based optimiza-
tion protocol [89]. Then, it ranked a total of 200 models created by their Rosetta energy 
score and provided the top 10 predicted models for the interaction, as well as their score 
and bb-RMSD from the starting conformation. 
GOLD. Local docking was performed using the GOLD (Genetic Optimization for 
Ligand Docking) program. GOLD uses a genetic algorithm that explores the binding 
pocket and searches for the best ligand interactions [41]. The energy minimized receptor-
SP40 peptide complex was loaded to the Hermes visualizer in the GOLD suite. The protein 
receptor was prepared by adding hydrogens and extracting the SP40 peptide ligand. The 
receptor-binding site was defined by reloading the extracted SP40 peptide. The search 
efficiency of the genetic algorithm was set to “automatic” and the option of “early termi-
nation” was switched off. The docking poses were ranked by the GoldScore scoring func-
tion. For docking with high accuracy, the number of “GA runs” was set to 150 (peptide 
length ×10). All other parameters were set as default. Then, according to GoldScore, the 
conformations for each peptide were collected and reranked. Higher GOLD scores repre-
sent a greater affinity of the ligand for the protein at the defined binding site. 
3.3. Analysis of Docking Results 
The 10 top-scoring solutions among the 150 runs provided by GOLD were exported 
using Hermes analyzed and visualized in Discovery Studios 4.2. The list of interactions 
was recorded and the bonds between the ligand (SP40 peptide) and receptors were ana-
lyzed.  
3.4. Receptor Blocking 
Human Rhabdomyosarcoma cells (RD) were grown overnight in wells within a 96-
well plate. Cells were treated with specific antibodies against each of the receptors. Anti-
annexin 2 (Novus Biological, Colorado, USA), anti-vimentin (Santa Cruz Biotechnology, 
Texas, USA), anti-SCARB-2 (R&D System, Minneapolis. USA), anti-PSGL-1 (Santa Cruz 
Biotechnology, Texas., USA), anti-heparan sulfate (Merck, New Jersey, United States), 
anti-galectin-1 (Abcam, Cambridge, UK) or anti-nucleolin (Abcam, Cambridge, UK) were 
incubated with RD cells for 1 h at 37 °C to block the receptors. After one hour, cells were 
washed with PBS and infected with EV-A71 (MOI 0.1) for 1 h. The inoculum was removed 
and treated cells were infected with EV-A71 (MOI 0.1) for 1 h. The inoculum was removed 
and DMEM media containing 2% FBS was added. After 24 h of incubation, the superna-
tants were collected to determine the virus titers by plaque assays as described by Lalani 
et al. [97].  
In the next experiment, the RD cells treated with the each of individual anti-receptors 
were further incubated with SP40 peptide (100 µM) for 1 h at 37 °C. Cells were then 
washed with PBS and infected with EV-A71 (MOI 0.1) for 1 h. The inoculum was removed 
and DMEM media containing 2% FBS was added. After 24 h of incubation, the superna-
tants were collected to determine the virus titers by plaque assays.  
Table 6 lists the details of the antibodies used in the experiment. The exact binding 
sites for most of the antibodies are proprietary information that were not available. All the 
antibodies were used at the maximum concentration which were found to be non-cyto-
toxic. 
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Annexin A2 Synthetic peptide within human Annexin A2 aa 20–60. 10  
Anti-vimentin Raised against purified Vimentin 20 
Anti-PSGL-1 
The antibody epitope was mapped to a site within a consensus 
tyrosine Sulfation motif of PSGL-1, previously shown to be es-
sential for interaction with P-selectin (and now shown to be es-




Heparan Sulphate Proteoglycan from EHS mouse tumour 20 
Anti-gelactin-1 
Synthetic peptide. This information is proprietary to Abcam 
and/or its suppliers 
20 
Anti-SCARB2 
Mouse myeloma cell line NS0-derived recombinant human 





Human nucleolin protein from Raji cell extract 20 
Anti-nucleolin  
(polyclonal) 
Synthetic peptide conjugated to KLH derived from within res-
idues 1–100 of Human Nucleolin 
20 
4. Conclusions 
Blocking the nucleolin receptor with anti-nucleolin showed the highest inhibition of 
viral infectivity and supported the local docking data predicted by the GOLD software. 
The fitness Goldscore of annexin A2, SCARB2 and human tryptophanyl-tRNA synthetase 
from local docking also indicated that they are likely to be involved in binding to EV-A71. 
The inhibition of SCARB2 by anti-SCARB2 only showed inhibition of infectivity at 51.04% 
but upon adding SP40 peptide which blocked nucleolin, the inhibition of infectivity rose 
significantly to 99.54%. The data indicated that the likelihood of treating EV-A71 infec-
tious with anti-SCARB2 and SP40 peptide 
Furthermore, local docking showed the ability of SP40 peptide for binding to differ-
ent cell receptors such as nucleolin, annexin A2, SCARB2 and hTrpRS with very close fit-
ness scores ranging from 125.3 to 108.5. The binding of SP40 to these receptors could in-
hibit the function of the receptors and inhibit any viruses that employ these receptors for 
their infectivity. For example, the binding of SP40 peptide to the RBDs of nucleolin was 
shown to inhibit poliovirus and hepatitis C virus (HCV) IRES-mediated translation. Das 
et al. [98] reported the inhibition of poliovirus and HCV in the presence of small (60 nt) 
RNA (IRNA) from Saccharomyces cerevisiae which was later shown by Izumi et al. [47] that 
the binding of IRNA to the RBDs of nucleolin could inhibit the translation of poliovirus. 
Besides nucleolin acting as the receptor for SP40 peptide, other receptors, such as 
annexin A2 and hTrpRS could serve as an additional attachment receptor. To further elu-
cidate the number of receptors involved in interacting with SP40 peptide to prevent the 
EV-A71 infection, knockdown of each of the receptors in RD cell could provide further 
insight. 
Thus, interactions analysis of the SP40 peptide to the cell receptors provided a clue 
for possible broad-spectrum antiviral activity of SP40 peptide against other viruses which 
use the same receptor(s) for infectivity. 
Meanwhile, this study highlighted the lack of high-resolution structures of several 
receptors. Additionally, the co-crystallization of peptides with any of the receptors in the 
study could provide more information on the potential binding site of the receptors that 
can be used for further in silico study to design new therapeutic peptides. 
Supplementary Materials: Table S1: General molecular docking of SP40 peptide with different tar-
get cellular receptors using AutoDock4 software, Figure S1: The first five binding pose of SP40 
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peptide interacting with the receptors in global molecular docking via HPEPDOCK Table S2: Fitness 
Gold score of local molecular docking of SP40 peptide with different target cellular receptors using 
GOLD software. 
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